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Abstract Pokeweed antiviral proteins (PAP) represent a family 
of protein toxins isolated from various organs and at different 
stages of development of Phytolacca americana (pokeweed). We 
isolated, sequenced and characterized for the first time a 
complete cDNA encoding a pokeweed antiviral protein expressed 
in seeds. The cDNA of PAP-S consists of 1249 nucleotides and 
encodes a mature 262 amino acid protein. Its predicted amino 
acid sequence is more similar to PAP (76%) than to PAP II 
(31%). It is known from literature that PAP-S is more active in 
inhibiting protein synthesis than other members of the PAP 
family. Therefore, the cDNA of PAP-S was expressed in 
Escherichia coli and the biological activity of the recombinant 
protein was compared with that of PAP purified from spring 
leaves. In a rabbit translation system, the median inhibitory 
concentrations (IC50) of recombinant PAP-S and native PAP 
were determined as 0.07 and 0.29 nM, respectively. Although the 
PAP-S protein in seeds is glycosylated, PAP-S can be expressed 
in Escherichia coli in a very active form, indicating that post-
translational modification in pokeweed does not seem to alter its 
ability to inhibit protein synthesis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Pokeweed antiviral protein is a potent cytotoxin isolated 
from several organs of the plant pokeweed (Phytolacca ame-
ricana). It attacks both procaryotic and eucaryotic ribosomes, 
removing a specific adenine base from the rRNA larger sub-
unit and thereby inhibits protein synthesis [1,2]. Thus PAP is a 
member of a family of RNA N-glysosidases called ribosome-
inactivating proteins (RIP) type I which all consist of a single-
chain protein [3]. The site attacked by RIPs is a single-
stranded loop, which is highly conserved in 28S, 26S, 23S 
and chloroplast rRNA. In E. coli 23 S rRNA, this loop has 
been shown to be involved in interactions with elongation 
factors EF-G and EF-Tu. 
Within the PAP gene family, different genes are expressed 
in various tissues and at different stages of development in 
Phytolacca americana. PAP, PAP II, PAP-S and PAP-R are 
the forms that appear in spring leaves, summer leaves, seeds 
and roots, respectively [4-7]. The molecular weight ranges 
from 29 kDa for PAP to 30 kDa for PAP-S and PAP II. 
Recently, several members of the PAP family were cloned 
and the nucleic acid sequences of PAP [8], PAP II [9] and 
the amino acid sequence of PAP-S [10] were determined. 
*Corresponding author. Fax: (32-2) 299-18-60 
Although PAP-S was identified as most effective in inhibiting 
protein synthesis in vitro [6], its nucleic acid sequence is still 
unknown. 
PAPs possess antiviral activity on a wide range of plant and 
human viruses. PAP-S inhibits infection of HEp-2 cells by 
herpes simplex virus and poliovirus [11] and also the replica-
tion of human immunodeficiency virus 1 (HIV-1) in isolated 
mononuclear blood cells infected in vitro [12]. In the latter 
study, PAP-S was more effective than other RIPs at inhibiting 
the expression of reverse transcriptase in infected cells. Dose 
response experiments indicated that the anti-HIV activity of 
PAP-S was comparable to AZT. Conjugation of PAP-S with 
monoclonal antibodies directed against CD4 and the HIV 
protein gpl20 dramatically increase its potency against human 
T cells infected with two different stains of the HIV virus [13]. 
Expression of PAP in transgenic plants leads to broad-spec-
trum resistance to viral infection [14]. Thus, PAPs offer new 
opportunities for possible application in therapy and as puta-
tive protective proteins in transgenic plants against pathogens. 
Since it has been shown that isozyme forms of various RIPs 
[15] may have different properties that may make one form 
more valuable than another for therapeutic applications, it 
was decided to clone and sequence the cDNA encoding the 
PAP-S protein. 
In this analysis, a cDNA library from pokeweed seeds was 
constructed and a complete cDNA encoding PAP-S was iden-
tified. The protein was expressed in E. coli and compared in 
detail to the activity of PAP produced in leaves of Phytolacca 
americana. The recombinant PAP-S was more active than 
native PAP in inhibiting eukaryotic in vitro translation. 
2. Material and methods 
2.1. Construction of the cDNA library 
Total RNA was extracted from the seeds of Phytolacca americana 
as described in reference [16]. Poly(A)+ RNA were purified on an 
oligo-dT column and used to synthesize cDNA with the 'TimeSaver 
cDNA Synthesis Kit' from Pharmacia. The cDNAs were inserted 
between the EcoRI sites of the .^ZipLox vector (Gibco BRL) and 
these recombinant DNAs were packaged in vitro using the X Pack-
aging System (Gibco BRL). The phages were amplified in E. coli 
Y1090 and subsequently more than 10° independent clones were 
screened. For the screening, a DNA fragment of PAP-S was amplified 
by reversed transcription-PCR. A primer (P9) was designed according 
to the known amino acid sequence of the protein [10], corresponding 
to the highly conserved region found in all RIPs and involved in the 
catalytic action of these proteins (5'-CGGGATCCCAT(G,A)-
TA(C,T)TT(G,A)AATCTIGCIGC(C,T)T-3') with a BamUl site. To-
tal RNA was reversed-transcribed as described previously [9] and the 
cDNA was amplified using P9 and a primer (P12) designed to the 
amino acid sequence of the N-terminus of PAP-S (5'-CCATCGAT-
GAT(C,T,A)AA(C,T)ACIAT(C,T,A)ACITT(C,T)GA(C,T)GC-3') 
with a Clal site. The amplified fragment (500 bp) was digested and 
cloned into the pBluescript KS+ vector (Stratagene) digested by Clal 
and BamHI. After sequencing, the fragment was used as a probe to 
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screen the cDNA library. Recombinant pZLl vectors were rescued 
from positive bacteriophage clones by in vivo excision according to 
the procedure provided by the manufacturer. The nucleotide sequence 
of the largest positive clone was determined in both directions using 
internal primers. Protein alignments were performed using the CLUS-
TAL program [17]. 
2.2. Construction of the PAP-S expression plasmid 
Primers P13 (5'-CTTCAGCTGATAAATACGATCACCTTT-
GATC-3') and P14 (5'-CGGGATCCGAATCCTTCAAATAGAT-
CAC-3') were designed to clone the PAP-S cDNA without the 
NH2-terminal extrapeptide into the isopropyl-pS-D-thiogalactopyrano-
side (IPTG)-inductible prokaryotic expression vector pQE60 (Qiagen), 
giving the vector pPAPS. The complete nucleotide sequence of the 
PCR reaction product was determined to verify that no mutation 
had occurred. 
2.3. Expression and purification of recombinant PAP-S 
The E. coli strain JM109 was transformed by pPAPS. The trans-
formants were grown at 37°C in LB medium containing ampicillin 
(100 ug/ml) to an optical density of 0.5 at 600 nm. After the addition 
of IPTG to a final concentration of 1 mM, culture was continued for 
2 h. The inclusion bodies containing the cytoplasmic recombinant 
protein were prepared as in [18], except for the last solubilization 
step done at room temperature for 1 h in a solution containing 10 
mM Tris-HCl (pH 8), 8 M urea, 0.2 M NaCl, 1 mM DTT, 10% 
glycerol and 1 mM EDTA. The solubilized proteins were renatured 
by dialysis against 10 mM Tris-HCl (pH 7.4), 0.1 M NaCl and cen-
trifuged at 15000Xg for 10 min. The supernatant was analyzed by 
SDS-polyacrylamide gel electrophoresis to estimate the purity of the 
recombinant protein. 
2.4. Inhibition of cell-free protein synthesis 
The enzyme activity of the purified recombinant protein was quan-
titated by a protein synthesis inhibition assay using a rabbit reticulo-
cyte system as described elsewhere [19]. Brome mosaic virus RNA was 
used as template mRNA. The incorporation of L-[35S]methionine into 
the TCA-precipitable product was measured by scintillation spectros-
copy. Purified PAP from pokeweed leaves was used as positive con-
trol. 
3. Results and discussion 
3.1. Cloning of PAP-S and sequence comparison 
Messenger RNA was purified from the seeds of Phytolacca 
americana and the corresponding cDNA library was synthe-
sized and cloned in ^.ZipLox. For the screening, the fragment 
corresponding to the NH2-terminal part of the protein was 
used. Several clones were identified and the largest one was 
sequenced. The complete sequence of PAP-S is shown in 
Fig. 1. 
The PAP-S cDNA clone has an open reading frame of 942 
bp and the total length of 1249 bp. The deduced polypeptide 
has a coding sequence of 314 amino acid residues. A compar-
ison of this sequence with that of PAP-S determined by direct 
amino acid sequencing [10] suggested that the cDNA encodes 
a protein containing extrapeptides of 24 and 28 amino acids at 
the NH2 -terminal and the COOH-terminal, respectively (Fig. 
1). According to the sequence, the theoretical molecular 
weight of mature PAP-S is 29 kDa. 
Alignment of the amino acid sequences of PAP-S, PAP, 
PAP II revealed that PAP-S is more similar to PAP (76% 
identity) than to PAP II (31% identity) (Fig. 2) indicating a 
higher degree of relatedness and less evolutionary diversifica-
tion among PAP and PAP-S. This is in line with recent evi-
dence of our laboratory, that a genomic gene for PAP II 
encodes two exons separated by one intron, whereas the ge-
nomic genes of PAP-S and PAP do not contain an intron 
(J.L. Poyet and A. Hoeveler, submitted). 
1 TCCAACGCAGAGCTCTCCATCACATCACATTGCATGTTCTCATAAAAAAAGCATCAGC'TC 
61 CTACGTACAACAGGTGAAAGTATTSAAAGAAGCGGCAAAGGGAAGATGAAGGTGATGCTT 
M K V M L 
121 GTAGTTGTGGTGACGTTAATAGCGTGGCTCATTCCTGCACCAACTTCAACTTGTGCCATA 
V V V V T L I A W L I A A P T S T C A 1 
181 AATACGATCACCTTTGATCCTGGAAATGCCACCATTAACAAATATGCCACCTTTATCGAA 
N T I T F D A G N A T I N K Y A T F M E 
241 TCTCTTCGTAATCAAGCGAAAGATCCAAAACTAAAATGCTATCGCATACCAAIGCTACCT 
S L R N Q A K D P K L K C Y G I P M L P 
301 GATACTAATTCGACCCCTAAGTACTTATTGGTTAAGCTCCAAGGTGCAAACCTAAAAACC 
D T N S T P K Y L L V K L Q G A N L K T 
361 ATTACACTAATGCTGAGACGAAATAACTTATACGTGATGGGCTATTCTGATCCCTTCAAT 
I T L M L R R N N L Y V M G Y S D P F N 
421 GGCAATAAGTGTCGTTACCATATATTTAATGATATTACAAGCACCGAACGCACTGATGTG 
G N K C R Y H I F N D I T S T E R T D V 
481 GAGAATACTCTTTGCTCAAGTTCTAGTTCICG'IGT'IGCMTGTCCATTAACTACAATAGC 
E N T L C S S S S S R V A M S I N Y N S 
541 rcATATCCGACCATGGAAAAGAAAGCAGAAGTAAACTCAAGAAATCAAGTCCAATTGGGA 
L Y P T H E K K A E V N S R N Q V Q L G 
601 ATTCAAATACTCAGCAGTOACATTGGAAAAATCTC'IGGAGT'IGATTCATTCCCTGTAAAA 
I Q I L S S D I G K I S G V D S F P V K 
661 ACTGAGGCTTTTTTTCTACTGGTAGCCATCCAAATGGTTTCAGAGGCAGCGCGATTCAAG 
T E A F F L L V A I Q M V S E A A R F K 
721 TACATAGAGAACCAAGTCAAGACTAATTTTAATAGAGCATTCTACCCTGATCCCAAAGTA 
Y I E N Q V K T N F N R A F Y P D P K V 
781 ATTAATTTGGAGGAGAAGTGGGGCAAAATCTCTGAGGCAATTCACAATGCCAAGAATGGG 
I N L E E K W G K I S E A I H N A K N G 
841 GCTTTACCCAAACCTCTAGAGCTAGTGGATGCCAAAGGTACCAAGTGGATAGTTCTTAGA 
A L P K P L E L V D A K G T K W I V L R 
901 GTGGATGAAATCAATCG'reATGTGGCACTCCTTAAGTACGTTAATGGAACCTGTCAGACA 
V D E I N R D V A L L K Y V N G T C Q T 
961 ACTTACCAAAATGCCATGTTCTCTCAAGTTATAATTTCTACTTATTATAATTATATGTCT 
T Y Q N A M F S Q V I I S T Y Y N Y M S 
1021 AATCTTGGTGATCTATTTGAAGGATTCTGATCATAGACATAATACGGAGTATATAAACTA 
N L G D L F E G F -
1081 TATTATAAAGCTTAAATAAGAGGCCGGGCCAATCGTACTTGTTGCCTTGTGCTATATGGT 
1141G TTGCTTATACATTGTATGCTTGTACTATATTAICTGATGAGAACAAGATGTACTGTGTA 
1201 GTCTTGTTTGAAATAAAACCATGCAATTCGATAGCAAAAAAAAAAAAAA 
Fig. 1. Nucleotide sequence and the deduced amino acid sequence 
of the PAP-S cDNA clone. The putative signal peptide (24 amino 
acids) is encoded by bases 107-178. The putative COOH-terminal 
extrapeptide (28 amino acids) is encoded by bases 964-1047. Bases 
178-963 encode a mature protein of 262 amino acids. The putative 
polyadenylation signal starts at base 1211 and the poly (A) tail starts 
at base 1236. 
The NH2-terminal extrapeptide shows features typical 
among secretory signal peptides [20], leaving the possibility 
to PAP-S to be targeted to a particular cellular compartment 
in the seeds. The exact subcellular location of PAP-S in poke-
weed seeds has not been determined, although several other 
seeds RIPs have been localized to protein bodies or vacuoles 
within endosperm cells [21]. N-glycosylation sites in the 
COOH-terminal extrapeptide, common to other plant pro-
teins that are targeted to vacuoles of the plant cell, were not 
observed in PAP-S. 
The cDNA deduced sequence of PAP-S identified in our 
study is very similar to the direct amino acid sequence deter-
mination of PAP-S protein isolated from seeds [10]. However, 
it is not identical (83% identity). The difference could be due 
to errors in direct protein sequencing as witnessed for ricin 
[22], to heterogeneity of PAP-S expressed in variants of poke-
weed or to different forms of PAP-S in seeds. Interestingly, 
Barbieri et al. demonstrated the presence of different forms of 
PAP-S in seeds [6]. 
In contrast to PAP and PAP II, the amino acid sequence of 
mature PAP-S contains three potential glycosylation sites at 
the amino acids residues 10, 44 and 255 (Fig. 2). These sites 
have been shown to contain a single JV-acetylglucosamine res-
idue [23]. The biological role of these glycosylations is not 
known. However, the glycosylations do not seem to be essen-
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PAP-S (N-terminal leader) 
PAP (N-terminal leader) 
PAP II (N-terminal leader) 
MKV-ML - W W T L I AWL IAAPTSTCA 
MKMSML-VVTISIV--LILAPTSTDA 
MKMKVLE WGLAISIWLMLTP-PAS S 
PAP-S 
PAP 
PAP II 
PAP-S 
PAP 
PAP II 
INTITFDAGNATINKYATFMESLRNQAKDPKLKCYGIPMLPDTNSTPKYL 
VNTIIYNVGSTTISKYATFLNDLRNEAKDPSLKCYGIPMLPNTNTNPKYV 
--NIVFDVENATPETYSNFLTSLREAVKDKKLTCHGMIMATTLTEQPKYV 
LVKLQGANLKTITLMLRRNNLYVMGYSDPFNGNKCRYHIFNDITSTERTD 
LVELQGSNKKTITLMLRRNNLYVMGYSDPFETNKCRYHIFNDISGTERQD 
LVDLKFGS-GTFTLAIRRGNLYLEGYSDIYNG-KCRYRIFKDSES D 
** * * ** ** * * * * * * * * * * * *+ * * 
50 
50 
48 
100 
100 
92 
PAP-S VENTLCSSSSSRVAM--SINYNSLYPTMEKKAEVNSRNQVQLGIQILSSD 148 
PAP VETTLCPNANSRVSK--NINFDSRYPTLESKAGVKSRSQVQLGIQILDSN 148 
PAP II AQETOCPGDKSKPGTQNNIPYEKSYKGMESKGG--ARTKLGLGKITLKSR 140 
* * * * * * * * * * * * 
PAP-S IGKISGVDSFPVK TEAFFLLVAIQMVSEAARFKYIENQVKTNFNRA 194 
PAP IGKISGVMSFTEK TEAEFLLVAIQMVSEAARFKYIENQVKTNFNRA 194 
PAP II MGKIYGKDATDQKQYQKNEAEFLLIAVQMVTEASRFKYIENKVKAKFDDA 190 
* * * * * * * 
* ** * * * * * * * ** * 
PAP-S 
PAP I 
PAP II 
PAP-S 
PAP 
PAP II 
—FYPDPKVINLEEKWGKISEAIHN AKNGALPKPLELVDAKGTKWIV 
—FNPNPKVLNLQETWGKISTAIHD AKNGVLPKPLELVDASGAKWIV 
NGYQPDPKAISLEKNWDSVSKVIAKVGTSGDSTVTLPGDLKDENNKPWTT 
LRVDEINRDV-ALLKYVUSTCQTTY-QNAMFSQVIISTYYNYMSNLGDLF 
LRVDEIKPDV-ALLNYVGGSCQTTYYQNAMFPQLIMSTYYNYMVNLGDLF 
ATMNDLKNDIMALLTHV--TCKV KSSMFPEIM—SYY-YRTSISNLG 
239 
239 
240 
287 
288 
282 
PAP-S 
PAP 
PAP II 
EGF 290 
EGF 291 
EFE 285 
Fig. 2. Alignment of cDNA deduced amino acid sequences of PAP-S, PAP and PAP II. Primary sequences are aligned to show maximum ho-
mologies. Identity (*) and similarity (') are indicated. Amino acid residues possibly involved in catalytic activity are indicated in bold face and 
the potential glycosylation sites of PAP-S are underlined. 
tial for the inhibitory activity, since PAP-S expressed in E. coli 
demonstrated biological activity similar to the native protein 
(see below). 
The three-dimensional structure of PAP and a-PAP, a pro-
tein related to PAP, have recently been elucidated [24,25]. By 
analogy with PAP, the tyrosine residues at position 72 and 
123 of PAP-S are expected to interact with the substrate, 
whereas glutamic acid at position 176 and arginine at position 
179 are involved in the catalytic activity (see Fig. 2). These 
residues were conserved in all PAP-isoforms studied so far. It 
can therefore be speculated that the overall structure and 
mechanism of action of all PAPs is similar. Moreover, a point 
mutation in the glutamic acid residue of PAP (here at position 
176), selected in a yeast system, inactivated the enzymatic 
function of PAP [26]. 
3.2. Expression of PAP-S in E. coli 
With the help of two primers containing appropriate restric-
tion sites at their 5'-ends, the cDNA of PAP-S without the 
NH2-extrapeptide but with the carboxy extension was cloned 
into the prokaryotic expression vector pQE60. The promoter 
of pQE60 gives high expression of foreign proteins in E. coli 
after induction by IPTG. The construct was transfected into 
the E. coli strain JM109 and the expression of PAP-S was 
induced by adding IPTG to the culture medium (Fig. 3). A 
protein band at approximately 32 kDa was readily visible on 
SDS-PAGE after induction with IPTG, corresponding to the 
expected molecular weight of mature PAP-S with the carboxy 
extension (lane 2, Fig. 3). Moreover, a monoclonal anti-PAP 
kDa 
116 
97 
84 
66 
55 
45 
36 
29 
Fig. 3. SDS-Polyacrylamide gel electrophoresis of PAP-S expressed 
in E. coli. Proteins analyzed were from cell containing the expres-
sion vector pPAPS with the addition of IPTG (lane 2) or without 
IPTG (lane 1). Lane 3: PAP-S purified from E. coli. The arrow in-
dicates the position of the recombinant protein. 
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Fig. 4. Inhibition of protein synthesis of recombinant PAP-S (closed 
boxes) in comparison with purified native PAP (open boxes) from 
spring leaves in a cell-free translation system from rabbit reticulo-
cytes. The results are expressed as percentage of L-[35S]methionine 
incorporation relative to that with (100%) and without (0%) tem-
plate mRNA. 
antibody, which was produced in our laboratory against PAP 
extracted from spring leaves, recognizing an epitope at the C-
terminus [27], crossreacted with the recombinant PAP-S (data 
not shown). 
In order to measure and to compare the capacity of PAP-S 
to inhibit eukaryotic protein translation to that of native 
PAP, recombinant PAP-S was purified from bacterial cell cul-
ture. As can be seen in Fig. 3 (lane 3), a single band was 
visible after the purification procedure, indicating the homo-
geneity of the preparation. The final yield of recombinant 
PAP-S was 5-8 mg/1 bacterial cell culture. 
3.3. Quantification of protein synthesis inhibition in a cell-free 
translation system 
Tests were carried out to measure the protein synthesis in-
hibition on a cell-free translation system with various concen-
trations of recombinant PAP-S or native PAP extracted from 
the leaves of Phytolacca americana (Fig. 4). 
In our experiments, PAP-S was more efficient than PAP 
isolated from spring leaves to inhibit in vitro protein synthesis 
using a rabbit reticulocyte system. The median inhibitory con-
centration of L-[35S]methionine incorporation (IC50) of re-
combinant PAP-S was 0.07 nM, whereas the IC50 value of 
PAP was determined as 0.29 nM. This is in very good agree-
ment with values given in the literature for PAP-S extracted 
from seeds (0.04 nM, [6]) and for PAP (0.24 nM, [4]). 
It is not known why PAP-S is more efficient at inhibiting 
protein synthesis than the other members of the PAP family. 
Recently however, a PAP-S based immunotoxin has been 
demonstrated to display powerful antitumor activity against 
CD30+ tumor cells in refractory Hodgkin disease and ana-
plastic large cell lymphoma [28]. In our studies we clearly 
show the efficient function of PAP-S as ribosome-inactivating 
protein in vitro. Furthermore, we were able to produce con-
sistent amounts of purified and highly active material. These 
results, together with the low aspecific toxicity for intact eu-
karyotic cells, may make PAP-S more suitable for the con-
struction of hybrid proteins and may facilitate the develop-
ment of therapeutic applications. 
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